Record Citations

APA (7th ed.) Citation
Keunchil Park, M., Daniel Shao Weng Tan, B., Wu-Chou Su, M., Byoung Chul Cho, M., Sang-We Kim, M., Ki Hyeong Lee, M., . . . Chia-Chi Lin, M. (2021). Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. Elsevier.
Chicago Style (17th ed.) Citation
Keunchil Park, MD, et al. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. Elsevier, 2021.
MLA (9th ed.) Citation
Keunchil Park, MD, et al. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. Elsevier, 2021.
Warning: These citations may not always be 100% accurate.